ONCOTYPE MAP™ PAN-CANCER TISSUE TEST

Covered by MEDICARE

Rapid Comprehensive Genomic Profiling to Aid Therapy Selection

The **Oncotype MAP™ Pan-Cancer Tissue** test is a **rapid comprehensive genomic profiling** (CGP) test that detects alterations in **257 genes** known to be drivers of cancer, and provides insights into available targeted and immuno-therapy treatment options for patients with advanced cancer in just **3-5 business days**.*†

Results are provided in an easy-to-interpret report which links actionable biomarkers to current therapy guidelines, to help guide treatment options. The report also includes potential evidence-based therapies and clinical trials.

Comprehensive

- 257 genes (SNVs, CNVs, fusions & structural variants).
- IO signatures including tumor mutational burden (TMB) and microsatellite instability (MSI).
- 24 immunohistochemistry (IHC) stains including PD-L1 (SP142, 22C3).

Fast Turnaround Time

- Results reported in 3-5 business days.*†
- Quantity not sufficient (QNS) results reported in as few as 2 business days.*

Accurate

- >99% sensitivity and specificity,‡ even on samples as small as 3 mm^2.*

Actionable

- 100+ therapies.
- 45+ combination therapies.
- 650+ clinical trials.

The Oncotype MAP test provides these **comprehensive insights** even in cases where biopsies are challenging. Testing can be performed on tissue samples as small as 3 mm^2 with just ≥15% tumor content* – about the size of a **grain of rice**.

To Learn More:	To Order:
OncotypeMAP.com	online.genomichealth.com

oncotype MAP™ Pan-Cancer Tissue

Paradigm Diagnostics, Inc., a wholly-owned subsidiary of Exact Sciences Corp.
445 N. 5th Street, Suite 300 | Phoenix, AZ 85004 | 866.662.6897 | exactsciences.com

EXACT SCIENCES

ONCOTYPE MAP™ PAN-CANCER TISSUE TEST **MARKERS**

257 GENE NGS PANEL

ABCB1	AREG	BUB1B	CYP19A1	EWSR1	GAS6	KEAP1	MYC	PIK3R1	RPTOR	TGFB2
ABCC1	ARID1A	CALR	CYP1A1	EZH2	GATA3	KIT	MYCN	PIM1	RRM1	TGFB3
ABCC2	ARID1B	CBL	CYP2D6	FAM175A	GLI1	KRAS	MYOD1	PLCB4	SDHB	TGFBR1
ABL1	ARID2	CCND1	CYP3A4	FANCA	GNA11	MAF	NBN	PLCG1	SDHC	TGFBR2
ACVR1	ATM	CCND2	CYSLTR2	FANCC	GNAQ	MAP2K1	NF1	PMS2	SETD2	TNFA1P3
ACVR1B	ATR	CCND3	DCK	FANCD2	GNAS	MAP2K2	NF2	POLD1	SF3B1	TNK1
ACVR2A	ATRX	CCNE1	DDR2	FANCE	GSTP1	MAP3K1	NFE2L2	POLE	SMAD1	TOP2A
ACVR2B	AURKA	CD274	DICER1	FANCF	HAMP	MAPK1	NOTCH1	PP2R1A	SMAD2	TP53
ACVRL1	AURKB	CDA	DNMT3A	FANCG	HDAC2	MAPK3	NOTCH2	PTCH1	SMAD4	TSC1
ADAMTS1	AXIN1	CDC73	**EGFR**	FANCM	HGF	MAPKAPK5	NOTCH3	PTEN	SMAD5	TSC2
ADAMTS6	AXL	CDH1	EMSY	FAT1	HNF1A	MDM2	NPM1	PTPN11	SMAD9	TSHR
ADAMTS9	B2M	CDK4	EP300	FBXW7	HRAS	MDM4	NRAS	RAD50	SMARCA4	TYMS
ADAMTS16	BAP1	CDK6	EPCAM	FCGR2A	HSD3B1	MED12	**NTRK1**	RAD51C	SMARCB1	VEGFA
ADAMTS18	BARD1	CDK12	EPHA5	FGD4	IDH1	MEN1	**NTRK2**	RAD51D	SMO	VHL
ADAMTSL1	BCOR	CDKN2A	EPHA7	FGF3	IDH2	**MET**	**NTRK3**	RAF1	SOCS1	WT1
AKT1	BMP6	CHEK1	ERBB2	FGF4	IGF1R	MGMT	PALB2	RB1	SPOP	XRCC1
AKT2	BMPR1A	CHEK2	ERBB3	**FGFR1**	IKZF1	MLH1	PBRM1	RBM10	STAG2	YES1
AKT3	BMPR1B	CHFR	ERBB4	**FGFR2**	IL6R	MPL	PDCD1LG2	RECQL	STAT3	
ALK	BNIP3	CHKA	ERCC1	**FGFR3**	JAK1	MRE11A	PDGFRA	**RET**	STAT5A	
AMER1	**BRAF**	CIC	ERCC2	FGFR4	JAK2	MSH2	PDGFRB	RHEB	STAT5B	
APC	BRCA1	CREBBP	ERCC3	FLT3	JAK3	MSH6	PIK3CA	RICTOR	STK11	
APLNR	BRCA2	CSF1R	ERRFI1	FLT4	KDM5C	MTHFR	PIK3CB	RIT1	SUFU	
AR	BRIP1	CTLA4	ESR1	FOXL2	KDM6A	MTOR	PIK3CD	RNF43	TERT-p	
ARAF	BTK	CTNNB1	ESR2	FUBP1	KDR	MUTYH	PIK3CG	**ROS1**	TGFB1	

Bolded genes include fusion detection.

IMMUNOHISTOCHEMISTRY (IHC)

SINGLE IHC STAINS

ALK	PD-L1 (22C3)
AR	PD-L1 (SP142)
CAIX	PR
ER	PTEN
hENTI	ROS1
HER2	TOP1
IDO	TP
MET	TRKpan
MGMT	TS
PD1	TUBB3

*MMR PANEL

MLH1	MSH6
MSH2	PMS2

TUMOR-SPECIFIC PANELS

Anal: PD-L1 (22C3), MMR*
Appendix: HER2, PTEN, MMR*
Bladder: PD-L1 (22C3), PD-L1 (SP142), MMR*
Breast: AR, PD-L1 (22C3), MMR*
Previously tested for HER2/ER/PR.
Otherwise HER2, ER, PR, PD-L1 (22C3), MSH6, PMS2.
Cervical: PD-L1 (22C3), ER, MMR*
Cholangiocarcinoma: HER2, PD-L1 (22C3), MMR*
CNS/Brain: MGMT, CAIX, MMR*
Colorectal: HER2, PTEN, MMR*
Esophagus: HER2, PD-L1 (22C3), MMR*
Gallbladder: HER2, PD-L1 (22C3), MMR*
Gastric: HER2, PD-L1 (22C3), MMR*
Head and Neck, Salivary Gland: HER2, AR, MMR*
Head and Neck, Squamous: PD-L1 (22C3), TUBB3, MMR*
Hepatocellular: HER2, PD-L1 (22C3), MMR*
Kidney: PD-L1 (22C3), MET, MMR*
Melanoma: PD-L1 (22C3), PTEN, MMR*
Mesothelioma: PD-L1 (22C3), TS, MMR*
Neuroendocrine: PD-L1 (22C3), PTEN, MMR*
NSCLC: PD-L1 (22C3), PD-L1 (SP142), ALK, MSH6, PMS2
Ovarian: ER, HER2, MMR*
Pancreatic: MMR*, PTEN, hENT1
Penile: PD-L1 (22C3), MMR*
Prostate: AR, PD-L1 (22C3), MMR*
Skin, Non-melanoma: PD-L1 (22C3), MMR*
Small Bowel: HER2, PTEN, MMR*
Soft Tissue: MMR*
Testicular: PD-L1 (22C3), MMR*
Thymus: PD-L1 (22C3), TUBB3, MMR*
Thyroid: PD-L1 (22C3), ALK, MMR*
Uterine: ER, HER2, MMR*
Vulvar: PD-L1 (22C3), ER, MMR*
Other Solid Tumors: PD-L1 (22C3), HER2, MMR*

Notes:
*Data on file.
†Turnaround time is based on qualified sample receipt.
‡>99% sensitivity for small variants (substitutions, insertions, and deletions). Detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity. Data on file.

Oncotype MAP Pan-Cancer Tissue, Oncotype MAP, and Oncotype are trademarks of Genomic Health, Inc. Exact Sciences and Cologuard are registered trademarks of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved. M-US-MAPt-00089_0322

About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps people get the answers they need to make more informed decisions across the cancer continuum. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Through an innovative, rigorous approach, and with the support of visionary collaborators, we're helping advance the fight against cancer.

oncotype MAP™ Pan-Cancer Tissue

Paradigm Diagnostics, Inc., a wholly-owned subsidiary of Exact Sciences Corp.
445 N. 5th Street, Suite 300 | Phoenix, AZ 85004 | 866.662.6897 | exactsciences.com

EXACT SCIENCES